iShares Genomics Immnlgy & Hlthcr ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
iShares Genomics Immunology and Healthcare ETF IDNA
Morningstar’s Analysis IDNA
Will IDNA outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.6
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Moderna Inc | 12.02 | 39M | Healthcare |
Twist Bioscience Corp | 6.02 | 19M | Healthcare |
Genmab AS | 5.16 | 17M | Healthcare |
Iovance Biotherapeutics Inc | 4.81 | 15M | Healthcare |
Takeda Pharmaceutical Co Ltd | 3.81 | 12M | Healthcare |
Regeneron Pharmaceuticals Inc | 3.64 | 12M | Healthcare |
Caris Life Sciences Inc | 3.58 | 11M | Healthcare |
Exelixis Inc | 3.54 | 11M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 3.53 | 11M | Healthcare |
Bayer AG | 3.50 | 11M | Healthcare |